Pharmaceutical News and Articles

Obstructive Sleep Apnea Tied to Nearly Doubled Risk for Flu, COVID-19 in Childhood

Children with obstructive sleep apnea (OSA) are nearly twice as likely to contract the flu or COVID-19, according to a study published online Feb. 11 in the Jou

Physical Activity May Reduce Risk for Death From Cancer

Moderate-to-vigorous physical activity (MVPA) may lower the risk for cancer mortality among cancer survivors, according to a study published online Feb. 17 in J

Geographic Variation Seen in Declines in Cervical Cancer Incidence

Declines in cervical cancer incidence among young U.S. women during the human papillomavirus (HPV) vaccination era vary by geographic region, according to a stu

Novartis Remibrutinib First Therapy to Achieve Phase III Primary Endpoint in Chronic Inducible Urticaria (CIndU)

Basel, February 18, 2026 Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urt

CagriSema Demonstrated 23% Weight Loss in an Open-Label Head-to-Head REDEFINE 4 Trial in People with Obesity, the Primary Endpoint Was Not Achieved

Bagsv rd, Denmark, 23 February 2026 Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical

Zepbound (tirzepatide), the Most Prescribed Weight Management Medication in 2025, Now Available in Multi-Dose KwikPen

Eli Lilly and Company (NYSE LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound (tirzepatide) to include th

FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Calquence Plus Venetoclax Approved in the US as First All-Oral, Fixed-Duration Combination for Patients with Chronic Lymphocytic Leukemia in the 1st-Line Setting

FDA Approves Bysanti (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia